Week Ending December 6, 2021

Senate Passes Rubio, Smith Resolution to Recognize November as National Lung Cancer Awareness Month
“Washington, D.C. — U.S. Senators Marco Rubio (R-FL) and Tina Smith (D-MN) applauded the U.S. Senate’s passage of their resolution to designate November 2021 as National Lung Cancer Awareness Month (S.Res.462). The resolution promotes the importance of early detection of lung cancer to help save lives. It also recognizes the need for research to improve early diagnosis, screening and treatment.”

Roundtable Discussion: Konduri Looks at Testing and Treatment Options for Patients With RET- and ROS1-Positive Lung Cancer
“During a Targeted OncologyTM Case-Based Roundtable event, Kartik Konduri, MD, hematologist/medical oncologist, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discussed the case of a 59-year-old patient with stage IVA adenocarcinoma of the lung.”

The Superhero Oncologist Who Saved My Friend From Cancer
“A woman explains how her close friend achieved remission from stage 4 lung cancer after being treated by Dr. Bret Friday – a superhero in her book.”

Community-Based Intervention May Increase Lung Cancer Screening
“Cost, lower literacy levels and fear of lung cancer diagnosis were highlighted as concerns with lung cancer screening.”

Battling Lung Cancer With CT Screening
“A team of MGH clinicians and other lung cancer advocates stopped by the Boston Fire Department District 3 firehouse on Cambridge Street Nov. 1 to kick off National Lung Cancer Awareness Month.”

Biodesix Partners with Spesana to Streamline Digital Access to Molecular Diagnostics for Precision Medicine in Lung Cancer
“MEMPHIS, Tenn.–(BUSINESS WIRE)–Spesana, the developer of a novel electronic operating system to unify EMRs, and Biodesix Inc. (NSDQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that they have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the United States utilizing Spesana’s digital platform solutions for comprehensive lung cancer management.”

Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer
“Jazz Pharmaceuticals, Inc.   (Nasdaq: JAZZ) today announced that the first patient was enrolled in a Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor Tecentriq® (atezolizumab) as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The trial, IMforte, conducted in collaboration with F. Hoffmann-La Roche Ltd, will measure the progression-free survival and overall survival benefits of Zepzelca and Tecentriq administered in combination compared to Tecentriq alone.”

Raleigh cancer survivor’s effort to help others earns her a national award and $50k for a local non-profit group
“RALEIGH, N.C. (WNCN) — A Raleigh woman who survived an often-deadly form of cancer is giving back to patients fighting the same disease. Her work just won her national recognition and a big award for a local nonprofit.”